Repurposing Dapagliflozin for Mitigation of the Kidney Injury Triggered by Cadmium in Rats: Role of Autophagy, Apoptosis, and the SIRT1/Nrf2/HO-1 Pathway
Hany H. Arab, Musaad M. Althobaiti, Abdulaziz S. Alharthi, Emad O. Almalki, Saif S. Alsoubie, Jawad M. Qattan, Saeed A. Almalki, Ahmed M. Ashour, Ahmed H. Eid · 2024
Read Repurposing Dapagliflozin for Mitigation of the Kidney Injury Triggered by Cadmium in Rats: Role of Autophagy, Apoptosis, and the SIRT1/Nrf2/HO-1 Pathway by Hany H. Arab, Musaad M. Althobaiti, Abdulaziz S. Alharthi, Emad O. Almalki, Saif S. Alsoubie, Jawad M. Qattan, Saeed A. Almalki, Ahmed M. Ashour, Ahmed H. Eid (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11678783.txt.
Description
Hany Arab and co-authors test whether a diabetes drug can shield rat kidneys from cadmium, in a 2024 study. Cadmium is a toxic metal that builds up in the body and damages kidneys. The drug, dapagliflozin, is known for antioxidant and cell-protecting effects in other models. Rats dosed with cadmium developed clear kidney injury, shown in tissue and blood markers.
Adding the drug eased the injury without lowering the metal stored in the kidney. It curbed the pro-oxidant response and switched on a protective pathway of defense genes. The drug also restored the cell's self-cleaning process and cut orderly cell death driven by the poison. The authors conclude the drug fights the damage chemistry, not the metal itself, and merits more study.
Catalog record
| CREATOR | Hany H. Arab, Musaad M. Althobaiti, Abdulaziz S. Alharthi, Emad O. Almalki, Saif S. Alsoubie, Jawad M. Qattan, Saeed A. Almalki, Ahmed M. Ashour, Ahmed H. Eid |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |